An Antibody-Recruiting Small Molecule That Targets HIV gp120

Department of Chemistry, Yale University, 225 Prospect Street, P.O. Box 208107, New Haven, Connecticut 06520-8107, USA.
Journal of the American Chemical Society (Impact Factor: 12.11). 11/2009; 131(45):16392-4. DOI: 10.1021/ja9057647
Source: PubMed

ABSTRACT HIV/AIDS is a global pandemic for which new treatment strategies are desperately needed. We have designed a novel small molecule, designated as ARM-H, that has the potential to interfere with HIV survival through two mechanisms: (1) by recruiting antibodies to gp120-expressing virus particles and infected human cells, thus enhancing their uptake and destruction by the human immune system, and (2) by binding the viral glycoprotein gp120, inhibiting its interaction with the human protein CD4 and preventing virus entry. Here we demonstrate that ARM-H is capable of simultaneously binding gp120, a component of the Env surface viral glycoprotein (found on the surface of both HIV and virus-infected cells) and anti-2,4-dinitrophenyl antibodies (already present in the human bloodstream). The ternary complex formed between the antibody, ARM-H, and gp120 is immunologically active and leads to the complement-mediated destruction of Env-expressing cells. Furthermore, ARM-H prevents virus entry into human T-cells and should therefore be capable of inhibiting virus replication through two mutually reinforcing mechanisms (inhibition of virus entry and antibody-mediated killing). These studies demonstrate the viable anti-HIV activity of antibody-recruiting small molecules and have the potential to initiate novel paradigms in HIV treatment.

Download full-text


Available from: Christopher Parker, Jul 17, 2014
21 Reads
  • Source
    • "Because carbonic anhydrase binds to benzenesulfonamide ligand with micromolar affinity,(8) we reasoned that the inclusion of this protein in the cell culture medium would result in its binding to the monolayer and therefore recruitment of the RGD motif to the surface, where it could mediate adhesion of the CHO cells. Ternary complex formation has been shown to be an efficient method of targeting antibodies to virus-infected cells.(9) "
    [Show abstract] [Hide abstract]
    ABSTRACT: This paper describes a molecular strategy to restore adhesion of cells to surfaces that otherwise do not present ligands that can mediate adhesion. The approach is based on a carbonic anhydrase fusion protein that binds benzenesulfonamides and that also includes the RGD peptide motif that can bind to cell-surface integrin adhesion receptors. In this way, the fusion protein can bind to a monolayer that presents the benzenesulfonamide ligand, thereby positioning the RGD peptide at the surface, where it can mediate the adhesion and spreading of cells. This strategy may provide a general method for promoting the adhesion of cells to non-natural surfaces or to defective biological matrices.
    Journal of the American Chemical Society 07/2010; 132(28):9733-7. DOI:10.1021/ja1016188 · 12.11 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Prostate cancer is the second leading cause of cancer-related death among the American male population, and society is in dire need of new approaches to treat this disease. Here we report the design, synthesis, and biological evaluation of a class of bifunctional small molecules called antibody-recruiting molecules targeting prostate cancer (ARM-Ps) that enhance the recognition of prostate cancer cells by the human immune system. ARM-P derivatives were designed rationally via the computational analysis of crystallographic data, and we demonstrate here that these materials are able to (1) bind prostate-specific membrane antigen (PSMA) with high affinity (high pM to low nM), (2) template the formation of ternary complexes of anti-DNP antibodies, ARM-P, and LNCaP human prostate cancer cells, and (3) mediate the antibody-dependent killing of LNCaP cells in the presence of human effector cells. This manuscript describes the application of fundamental chemical principles to the design of a novel class of molecules with high therapeutic potential. We believe that this general small-molecule-based strategy could give rise to novel directions in treating cancer and other diseases.
    Journal of the American Chemical Society 11/2009; 131(47):17090-2. DOI:10.1021/ja906844e · 12.11 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: (Figure Presented) Aptamer-programmed antibodies: An RNA aptamer was covalently attached to antibody 38C2 (see scheme) to provide an aptamer-programmed antibody with significantly higher affinity and improved pharmacokinetic properties compared to the parent aptamer. This strategy may provide a promising new class of immunotherapeutics that derive their specificity from nucleic acids.
    Angewandte Chemie International Edition 08/2010; 49(34):5934-7. DOI:10.1002/anie.201001736 · 11.26 Impact Factor
Show more